IL236495A0
(en )
2015-02-26
Heteroaromatic compounds as bruton's tyrosine kinase (btk)inhibitors
CL2014001765A1
(en )
2014-10-03
Process for the manufacture of 1- [2- (2,4-dimethylphenylsulfanyl) phenyl] piperazine.
DK3686193T3
(en )
2022-05-30
2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE COMPOUNDS
DK2806859T3
(en )
2019-08-05
FORMULATIONS OF 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) CYCLOPROPANCARBOXAMIDO) -3-METHYLPYRIDIN-2-YL) BENZOIC ACID
SMT201500091B
(en )
2015-05-05
Bis (fluoroachyl) -1,4-benzodiazepinone compounds
IL238571A0
(en )
2015-06-30
Bruton's tyrosine kinase inhibitors
DK3074396T3
(en )
2019-07-29
1- (5-tert-butyl-2-arylpyrazole-3-yl) -3- [2-fluoro-4 - [(3-oxo-4H-pyrido [2,3-b] pyrazine-8-yl) oxy ] PHENYL] URINE DERIVATIVES AS RAF INHIBITORS FOR CANCER TREATMENT
UY34765A
(en )
2013-11-29
NEW COMPOUNDS.
BR112013025792A2
(en )
2018-04-24
PYRROID-RELATED KINASE INHIBITORS [2,3-D] PYRIMIDINE TROPOMISINE
UY34778A
(en )
2013-12-31
? HEXAHYDROPIRANE COMPOUNDS [3,4-d] [1,3] HETEROCYCLIC TIAZIN-2-AMINA SUBSTITUTED.
BR112014031635A2
(en )
2017-06-27
(e) -n-methyl-n- ((3-methylbenzofuran-2-yl) methyl) -3- (7-oxo-5,6,7,8-tetrahydro-1,8-) prodrug derivatives naphthyrindin-3-yl) acrylamide
BR112015005361A2
(en )
2017-07-04
bruton tyrosine kinase inhibitors
DK3054927T3
(en )
2019-05-13
FORMULATIONS OF (S) -3- (4 - ((4-MORPHOLINOMETHYL) BENZYLXYL) -1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE
IL231958A0
(en )
2014-05-28
Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2- trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
UY34329A
(en )
2013-04-30
TRIAZOLOPIRIDINE COMPOUNDS
CL2014003459A1
(en )
2015-08-28
Heterocyclic fungicidal compounds.
SMT201600421B
(en )
2017-01-10
7-METHYL-2- [4-METHYL-6- [4- (trifluoromethyl) phenyl] pyrimidin-2-IL] -1,7-diazaspiro [4.4] nonan-6-ONE
UY34791A
(en )
2013-11-29
N-ETHYL-4-HYDROXYL-1-METHYL-5- (METHYL (2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) -2-OXO-N-PHENYL-1,2- DIHYDROQUINOLINE-3-CARBOXAMIDE
DK2748147T3
(en )
2017-11-13
Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
CL2013000797A1
(en )
2013-09-13
Preparation process for (2r, 3r) -3- {4- (s- (cyclo) alkyl-sulfonimidoyl) phenyl} amino} -5- (trifluoromethyl) pyrimidin-4-yl} oxy} butan-2-2ol inhibitors; and the intermediary compounds considered.
TH148782B
(en )
2016-04-18
Dosage form (S) - ethyl-2-amino-3- (4- (2- amino-6 - ((R) -1- (4- chloro-2- (3-methyl- 1H-pyrazol-1-il) phenyl) -2,2,2-trifluoroethoxy) pyrimidin-4-il) phenyl) propano Et ((S) -ethyl-2-amino-3- (4- (2-amino-6 - ((R) -1- (4-chloro-2- (3-methyl-1H-pyrazol-1-y1)) phenyl) -2,2,2-trifluoroethoxy) pyrimidin-4-yl) phenyl) propanoate)
DK3057580T3
(en )
2021-05-10
PHARMACEUTICAL FORM OF ADMINISTRATION CONTAINING SODIUM-1- [6- (MORPHOLIN-4-YL) PYRIMIDIN-4-YL] -4- (1H-1,2,3-TRIAZOL-1-YL) -1H-PYRAZOLE-5-OLATE
CL2014001265A1
(en )
2014-08-22
Compounds derived from uracil, axl and c-met kinase inhibitors, useful in the treatment of cancer.
CU20120001U
(en )
2014-01-29
GATEADOR, WALKER, CORRAL
ITPT20130011U1
(en )
2015-04-02
ANATOMIC INSOLE CONCAVE, FOR SANDALS IN GENERAL